What this evidence supports
FDA reports significant growth in drug application submissions that include AI components across the drug-development lifecycle.
What it does not establish
FDA's statement describes an agency-reported submission trend, not an approval count, comparative-performance finding, or blanket endorsement of an AI method, submission, or output.
Answer-ready summary
FDA CDER reports increasing use of AI across drug-development submissions.
Record details
- Decision priority
- Watch
- Current status
- Current FDA regulatory-trend statement · not endorsement of a method or submission
- Evidence tracks
- Science/market · Technologies/care models
- Source authority
- Primary/authoritative
- Source organization
- FDA CDER
- Evidence design
- Federal regulatory trend
- Applicability
- Applicable to decisions about the stated program, policy, standard, or development context; not evidence of clinical benefit beyond the cited scope.
- Confidence for the stated claim
- High
- Freshness
- Current
- Record date
- 2026-05-01
- Source updated
- 2026-05-01
- Last verified
- 2026-09-03
- Review due
- 2026-10-03 or sooner if the cited source changes.
- Version
- 1.1
- Revision state
- Version 1.1 records the September 3, 2026 re-verification and May 1, 2026 source-current date and clarifies that FDA describes a submission trend, not approvals, comparative performance, or endorsement.
Evidence record fields
- Claim supported
- FDA reports significant growth in drug application submissions that include AI components across the drug-development lifecycle.
- Source type and design
- Federal regulatory trend
- Population and setting
- Not a participant-level clinical-study population in this source type. The program, policy, regulatory, standards, or research context described by the cited source.
- Intervention/exposure and comparator
- Not evaluated as a comparative intervention or exposure in the cited administrative or program source. No comparator is reported for this source-bounded claim.
- Outcome or endpoint
- The program, policy, regulatory, standards, or development state stated in the claim supported; no clinical outcome is inferred.
- Follow-up duration
- No clinical follow-up duration is reported for this source-bounded claim.
- Effect estimate and uncertainty
- No clinical effect estimate is reported. No statistical uncertainty estimate is reported; uncertainty is bounded through the source scope and stated limitations.
- Harms/adverse events
- No harms or adverse-event analysis is reported for this source-bounded administrative or program claim.
- Missing data and attrition
- Not reported; this record does not analyze participant-level data. Not applicable or not reported; no longitudinal participant cohort is analyzed.
- Bias/limitations
- FDA's statement describes an agency-reported submission trend, not an approval count, comparative-performance finding, or blanket endorsement of an AI method, submission, or output.
- Applicability/generalizability
- Applicable to decisions about the stated program, policy, standard, or development context; not evidence of clinical benefit beyond the cited scope.
- Funding/conflicts
- Funding or sponsorship is recorded only where the cited source and claim state it; otherwise it is not assessed in this record. No conflict-of-interest assessment is reported for this administrative or program-source record.
- Replication or corroboration
- The administrative or program claim is anchored to the cited authoritative source; independent clinical replication is not implied.
- Decision use
- Use as source-bounded context for Clinicians, Innovators, Health-system leaders, Policymakers; do not use as stand-alone evidence of safety, efficacy, coverage, endorsement, or scaled adoption.
- Last reviewed / review due
- Last reviewed 2026-09-03; review due 2026-10-03 or sooner if the cited source changes.
For this decision
Clinicians · Innovators · Health-system leaders · Policymakers